Armata Pharmaceuticals Announces Second Quarter Results and Provides General Corporate Update prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Armata Pharmaceuticals Announces First Quarter Results and Provides General Corporate Update
Company earns $750,000 milestone payment related to SWARM-P.a. Study
News provided by
Share this article
Share this article
MARINA DEL REY, Calif., May 13, 2021 /PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ( Armata or the Company ), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the first quarter of 2021 and provided a corporate update.
First Quarter 2021 and Recent Highlights:
Continued to advance the single ascending dose (SAD) cohort of the SWARM-
P.a. Phase 1b/2a clinical trial evaluating AP-PA02 as a potential treatment for cystic fibrosis patients with chronic
PureTech Announces Annual Results for Year Ended December 31, 2020
By
Staff
2 seconds ago
Strong capital base and cash runway extended into the first quarter of 2025, with PureTech level cash and cash equivalents of $443.4 million as of March 31, 2021
1 ($349.4 million as of December 31, 2020
2) and consolidated cash and cash equivalents of $486.5 million as of March 31, 2021
3 ($403.9 million as of December 31, 2020
4)
Advancement of Wholly Owned Pipeline with four clinical trial initiations and one successful readout, with three clinical trials ongoing
Significant milestones across PureTech’s Founded Entities including one FDA Clearance for Marketing, two European Marketing Authorizations, initiation of a Phase 3 program, $247.8 million raised in 2020
5 and $473.2 million raised in the 2021 post-period
KINNEAR PHARMACEUTICALS ANNOUNCES FUNDING AGREEMENT WITH THE CYSTIC FIBROSIS FOUNDATION texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
iCrowdNewswire Jan 26, 2021 9:00 AM ET
Support for preclinical testing for a novel broad spectrum inhaled anti-infective that rapidly eradicates microbial biofilms which are present in the lungs of Cystic Fibrosis patients
DUBLIN,OHIO (26 January 2021) Kinnear Pharmaceuticals (Kinnear)announces an agreement with the Cystic Fibrosis Foundation on a staged Therapeutic Development Award (TDA) providing development funds for Kinnear’s lead compound, CSA-131. The staged award of up to $3 million, supported with matching funds from Kinnear, provides funding for preclinical research to enable the filing of an Investigational New Drug (IND) application with the FDA in 2022.
“We are pleased and honored to announce this agreement with the Cystic Fibrosis Foundation to help progress CSA-131 as a novel therapeutic drug candidate for CF lung infections. Individuals living with CF are frequently burdened with life-threatening lung infections resulting from highly drug-resistant bacte